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Objective: Scottish fold cats, named for their unique ear shape, have a dominantly inherited osteo-
chondrodysplasia involving malformation in the distal forelimbs, distal hindlimbs and tail, and pro-
gressive joint destruction. This study aimed to identify the gene and the underlying variant responsible
for the osteochondrodysplasia.
Design: DNA samples from 44 Scottish fold and 54 control cats were genotyped using a feline DNA array
and a caseecontrol genome-wide association analysis conducted. The gene encoding a calcium
permeable ion channel, transient receptor potential cation channel, subfamily V, member 4 (TRPV4) was
identiﬁed as a candidate within the associated region and sequenced. Stably transfected HEK293 cells
were used to compare wild-type and mutant TRPV4 expression, cell surface localisation and responses to
activation with a synthetic agonist GSK1016709A, hypo-osmolarity, and protease-activated receptor 2
stimulation.
Results: The dominantly inherited folded ear and osteochondrodysplasia in Scottish fold cats is associ-
ated with a p.V342F substitution (c.1024G>T) in TRPV4. The change was not found in 648 unaffected cats.
Functional analysis in HEK293 cells showed V342F mutant TRPV4 was poorly expressed at the cell
surface compared to wild-type TRPV4 and as a consequence the maximum response to a synthetic
agonist was reduced. Mutant TRPV4 channels had a higher basal activity and an increased response to
hypotonic conditions.
Conclusions: Access to a naturally-occurring TRPV4 mutation in the Scottish fold cat will allow further
functional studies to identify how and why the mutations affect cartilage and bone development.
© 2016 The Authors. Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
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Osteochondrodysplasias (or skeletal dysplasias) are a hetero-
geneous group of disorders caused by structural, metabolic and
endocrine defects that compromise cartilage and/or bone growth
and give rise to a malformed skeleton1e3. Skeletal development is a
highly complex process inﬂuenced by a vast number of genes and
precise tuning of these genes is essential for normal skeletal
development. Although individual skeletal dysplasias are rare in
humans, research into their pathogenesis has provided valuable
insights into bone and cartilage development, as well as more
common connective tissue disorders such as osteoarthritis2,4e6.
One of the biggest challenges in the post-genome era is ana-
lysing and dissecting complex and quantitative traits. While such
analyses remain a challenge, companion animals provide powerful
model populations to study underlying genetic mechanisms. As
most dog and cat breeds have been developed within the last 200
years, the remarkable phenotypic and genetic diversity observed
today is the result of intense artiﬁcial selection. Founder effects at
breed creation and subsequent line-breeding have resulted in the
unique genetic background of breeds with extensive linkage
disequilibrium and long haplotype blocks, compared to human
populations7,8. While this process has reduced the overall genetic
heterogeneity within breeds, it has also enriched alleles with large
effects on favourable traits. This population structure is highly ad-
vantageous for genome-wide association studies (GWAS) as fewer
markers and fewer individuals are required to map even complex
traits9. An undesirable consequence of the intensive selection for
breed-speciﬁc traits has been the accumulation of various disease
alleles and a high frequency of genetic disorders in many dog and
cat breeds. For a remarkable number of these, analogous human
genetic disorders are known (http://omia.angis.org.au/home/).
Recent advances in feline genomics, including a whole-genome
reference sequence10, and a feline DNA genotyping array11, have
enabled GWAS in cats and allow the cat to be used as a model
species to gain insights into the molecular mechanisms underlying
human genetic disorders.
Scottish fold cats are characterized by their unique ear shape,
caused presumably by reduced resilience of the pinna cartilage.
While affected kittens are bornwith straight ears, the pinnae begin
to fold forward at around three to four weeks of age. Based on
pedigree information and breeding experiments, the Scottish fold
phenotype is inherited as a highly penetrant autosomal dominant
trait12e14. A congenital degenerative osteochondrodysplasia char-
acterised bymalformations in the distal forelimbs, distal hind limbs
and tail was initially thought to be restricted to homozygousmutant
cats, but was subsequently identiﬁed in heterozygous mutant
cats12,15,16. Based on the initial ﬁnding the breeding recommenda-
tion for Scottish fold cats is tomate fold-eared cats onlywith normal
eared-cats toavoidproducinghomozygousmutant cats. Preliminary
histologic examinations suggested chondrocyte cell death in artic-
ular cartilage, and disturbed maturation of proliferative chon-
drocytes to hypertrophic chondrocytes in the growth plate16.
Radiographic examinations suggest defective endochondral ossiﬁ-
cation resulting in variably reduced length and abnormal shape of
the metatarsal and metacarpal bones, accompanied by accelerated
degenerative joint disease and progressive peri-articular new bone
formation. Interestingly, the age at onset of clinical signs, as well as
severity and theprogression of the secondarynewbone formation is
highly variable among affected heterozygous cats. Whether genetic
or environmental factors are responsible for the observed pheno-
typic differences is yet to be determined.
The present study used genetic, computational and in vitro
strategies to identify the gene underlying the Scottish fold osteo-
chondrodysplasia phenotype. A missense variant in the TransientReceptor Potential Vanilloid family member 4 gene (TRPV4) is asso-
ciated with ear folding, abnormal distal appendicular bones and a
progressive degenerative joint disorder with different degrees of
severity.
Material and methods
Animals and SNP array genotyping
All samples were collected with the permission of the cat's
owner, under University of California e Davis institution animal
care and use protocol 15933 and with approval of the University of
Sydney Animal Ethics Committee (N00/10-2012/3/5837). Cats were
sourced from different Scottish fold/Scottish shorthair populations
in Europe, Australia and the USA. Radiographs were available from
three severely affected Scottish fold cats. One severely affected cat
was studied using standard radiography, a helical computerised
tomography (CT) and scintigraphy following an intravenous
technetium-99m injection to highlight regions with increased bone
remodelling. EDTA anti-coagulated blood or non-invasive buccal
swab samples were collected from 44 cases (Scottish fold) and 54
controls (22 Scottish shorthairs e strait eared siblings of cats with
folded ears, 14 British shorthairs, 13 Selkirk rex and ﬁve Persian
cats). Genomic DNA was isolated using the DNAeasy Kit (Qiagen,
Hilden, Germany) and concentrated using the Genomic DNA Clean
& Concentrator Kit (Zymo Research, Irvine, USA) when necessary.
Individual genotypes were determined using the Illumina Inﬁnium
Feline 63K iSelect DNA array.
Genome-wide association study and ﬁne mapping
Array marker locations were adjusted to the most recent feline
genome assembly Felis catus 6.2/felCat511. A caseecontrol genome-
wide association analysis was performed as previously described11.
The population substructure within cases and controls was evalu-
ated using a multi-dimensional scaling (MDS) plot with two di-
mensions and the identical-by-state (IBS) allele-sharing proportion
was calculated for each individual using PLINK17. Outlier samples
and individuals with a proportion of IBS >0.3 were excluded. The
GWAS results were adjusted for multiple testing (-mperm 100,000)
using PLINK17. The threshold for genome-wide signiﬁcance was
Bonferroni-adjusted. Linkage disequilibrium and haplotypes in the
region from position 23,500,000 to 25,5000,000 of feline chro-
mosome D3 were determined using HAPLOVIEW18. The corre-
sponding syntenic region in the mouse genome was searched for
potential candidate genes using the Mouse Genome Browser
(http://gbrowse.informatics.jax.org/cgi-bin/gb2/gbrowse/
mousebuild38/).
PCR and variant analysis
Five cats including two cases (Scottish folds) and three straight-
eared controls (one Scottish-shorthair and two domestic short-
hairs) were selected for initial variant detection. Primers to amplify
the 15 TRPV4 coding exons (exons 2e16) including the 50- and 30-
untranslated regions were designed using Primer 3 software
(http://biotools.umassmed.edu/bioapps/primer3_www.cgi).
Primer sequences are listed in Table S1. PCR products were ampli-
ﬁed using the SequalPrep long range PCR kit (Invitrogen, Carlsbad,
USA) according to the manufacturer's protocol. An additional
primer set was designed for exon 6. PCR products for exon 6 were
ampliﬁed in 20 ml reactions using AmpliTaq Gold according to the
manufacturer's protocol (Applied Biosystems, Foster City, USA). PCR
products were treated with shrimp alkaline phosphatase (Roche,
Basel, Switzerland) and exonuclease I (New England Biolabs,
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well as internal sequencing primers when necessary. Sequencing
products were separated using an ABI 3730 capillary sequencer
(Applied Biosystems, Foster City, USA), analysed using Sequencher
4.8 (GeneCodes, Ann Arbor, USA) and compared to the feline
reference sequence felCat5 September 2011 build. The candidate
causative variant was genotyped in all additional Scottish fold and
Scottish shorthair samples available (42 Scottish fold and 21 Scot-
tish shorthair). The possible impact of candidate variants on the
protein structure was investigated using PolyPhen-2 (http://
genetics.bwh.harvard.edu/pph2/).
Population screening
An allele-speciﬁc PCR assay was developed to detect the
c.1024G>T polymorphism. Cats (n ¼ 728) from 40 different pop-
ulations, including pure-breed and random bred cats, were ana-
lysed. Each 25 ml PCR reaction contained template DNA, 1 mM of
each primer (forward FAM-AACTACCTGACAGAGAACCCG, the wild-
type reverse tgatCAGGTCGTACATCTTGGTGgC and the affected
reverse CAGGTCGTACATCTTGGcGAA), 1  PCR Buffer (Denville
Scientiﬁc Inc., South Plainﬁeld, USA), 2.5 mM MgCl2, 1.0 mM each
dNTP, 0.02 ml DMSO and 1.0 U Choice-Taq DNA polymerase (Den-
ville Scientiﬁc, Inc., South Plainﬁeld, USA). Template speciﬁcity was
increased by incorporating a sequence mismatch in both reverse
primers (lower case letter) and the addition of four mismatched
bases (lowercase underlined) to create a visually detectable pro-
duce size difference. PCR amplicons were visualized on an ABI 3730
DNA Analyzer (Applied Biosystems, Foster City, USA) and analyzed
using STRand software19.
Feline TRPV4 homology modelling
The Protein Data Bank (PDB)20 was searched for structural
templates for the feline TRPV4 protein (XP_003994899.1) using
PSI-BLAST21. The top ranked human template was used to construct
the 3D homologymodel. The felinewild-type sequencewas aligned
to the human template using CLUSTAL-W22 and the 3D homology
model of the aligned TRPV4 N-terminal domain (residues 148-397)
was illustrated using MODELLER23.
Expression of normal and mutant TRPV4 in HEK293 cells
Human TRPV4 cDNA in pcDNA5/FRT/TO (Invitrogen, Carlsbad,
USA) has been described previously24. Human and cat TRPV4 pro-
teins are the same length and the amino acid sequences are 97%
identical. The V342F mutation was introduced using the Quik-
Change® II XL Site-Directed Mutagenesis Kit (Agilent Technologies)
and the entire coding region of the cDNA construct was sequenced
to conﬁrm that PCR errors had not been introduced. Flp-In™ T-
Rex™-293 cells (Life Technologies, Carlsbad, USA) were transfected
using Lipofectamine™ (Life Technologies, Carlsbad, USA) and stably
transfected cells selected for ﬁve passages with 5 mg/ml blasticidin
and 100 mg/ml hygromycin. TRPV4 expression was induced with
1 mg/ml tetracycline for four hours.
Preparation of total cell protein and cell surface biotinylated
proteins and immunoblotting
Total cell protein and biotinylated cell surface proteins were
isolated and analyzed by immunoblotting as described previously24
using a rabbit polyclonal TRPV4 antibody (ab39260, Abcam, Cam-
bridge, UK), a monoclonal anti-actin antibody (A3853, Sigma
Aldrich, St. Louise, USA), or an anti-transferrin receptor antibody
(13-6800, Life Technologies, Carlsbad, USA) and Alexa Fluor®-conjugated secondary antibodies (Life Technologies, Carlsbad, USA).
Immunoblots were imaged using a Typhoon™ TRIO Variable Mode
Imager (GE Healthcare, Little Chalfont, UK) and bands quantiﬁed
using ImageQuant TL Software (GE Healthcare, Little Chalfont, UK).
Intracellular calcium measurement
Intracellular calcium ([Ca2þ]i)wasmeasuredbyﬂuorescencewith
a FlexStation III (Molecular Devices, Sunnyvale, USA), as described
previously24. A total of 16,000 cells/well were plated into poly-L-
lysine coated 384 well plates, grown for 48 h, TRPV4 expression
inducedwith tetracycline for 4 h, before cells were loadedwith 2 mM
Fura-2 AM (Molecular Probes, Eugene, USA) for 1 h in the presence of
0.01% pluronic F-127. Loading and experiments were done as
described before24. Emission intensity was measured at 520 nm in
response to the synthetic TRPV4 agonist GSK1016709A, hypo-
osmolarity (240 mOsm) and the protease-activated receptor 2
(PAR2) activatingpeptideSLIGRL (50mM;Sigma) for120s, at intervals
of 5.86 s, using excitation wavelengths of 340 and 380 nm. Four in-
dependent FlexStation experiments, eachwith six determinations at
each point, were combined and expressed as means ± S.E.M (n ¼ 4).
Curve ﬁtting and statistics were done using GraphPad Prism 6. One
way ANOVA was used for multiple comparisons when there was a
single treatment and two-way ANOVA for multiple comparisons
when there were multiple treatments or time points.
Results
Radiographic ﬁndings
The skeletal phenotype in the Scottish fold cats heterozygous for
the missense mutation in exon 6 ranged from mild to severe. Ra-
diographs showed all metatarsal and metacarpal bones are short-
ened and malformed; some are bent with enlarged proximal and
distal epiphyses (Fig.1, Fig. S1). Intertarsal and tarsometatarsal joint
spaces are irregular, indistinct and narrowed (Fig. S1). The corre-
sponding joints in the forelimbs are similarly affected, although
generally to a lesser extent. All Scottish fold cats showed peri-
articular new bone formation (Fig. 2, Fig. S2), which was along
the proximal metatarsal bones, and the distal tarsal bones. The
peri-articular new bone appeared smooth in plain radiographs, but
the superior resolution of CT and elimination of superimposition
demonstrated that new bone was actually laid down irregularly
(Fig. 2). The proximal limb joints, long bones of the limbs and the
vertebral column were unaffected.
Genome-wide association study
Ninety-eight cats (44 cases and 54 controls) were genotyped on
the Illumina Inﬁnium iSelect Feline 63KDNAgenotyping array. After
quality check 46,203 SNPs, 35 Scottish fold and 32 controls (17
Scottish Shorthair, 8 Selkirk Rex, 3 British Shorthair and 4 Persian)
remained for analysis (Fig. S3 (A)e(B)). The analysis identiﬁed a
signiﬁcant association on feline chromosome D3, with one SNP at
position D3:24,861,228 bp reaching genome-wide signiﬁcance after
correction for multiple testing (Praw ¼ 4.7$1011, Pgenome ¼ 0.00001)
(Fig. 3). A haplotype block deﬁned in Haploview18 spanning the in-
terval from D3:24,380,099 bp to D3:25,202,262 bp, harbouring the
highest associated SNP, was identiﬁed with a frequency of 50% in
affected cats (Fig. S4). The haplotypewas unique to cases, suggesting
association with the dominant trait. Based on the feline genome
assembly F. catus 6.2/felCat5, this haplotype block contained 23
annotated genes (Table S2). Investigation of the syntenic region in
the mouse genome identiﬁed TRPV4 as the strongest positional
candidate gene.
Fig. 1. Radiographs of a severely affected Scottish fold cat. (A) Dorsopalmar view of the distal forelimbs. Carpal and carpometacarpal joint spaces are narrowed. Metacarpal bones
are shortened. (B) Dorsomedial-plantarolateral oblique view of the distal hind limbs. Metatarsal bones are shortened. A mass of smoothly marginated ankylosing new bone is visible
on the plantar aspect of the tibiotarsal, intertarsal and tarsometatarsal joints. Distal intertarsal and tarsometatarsal joint spaces are narrowed.
Fig. 2. Radiological ﬁndings in the right distal hindlimb of a severely affected Scottish Fold cat. (A) Lateral radiograph. (B) Three-dimensional volume-rendered computed to-
mography image. (C) Bone phase scintigraphic image showing the irregularly proliferative area of active bone remodelling (arrows) associated with individual metatarsophalangeal
joints.
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The TRPV4 coding sequence (GenBank accession no.
XM_003994850.2) was analysed in two cases and three controls.
Comparison of all 15 coding exons, including partial intronic
sequence, revealed 26 sequence variants (Table I). Eleven variants
were located in the coding sequence and ﬁve changed the amino
acid sequence. Only one exonic variant showed concordance with
the folded ear phenotype. Both Scottish fold cats were heterozy-
gous for a missense variant located in exon 6 (c.1024G>T) that was
absent in three straight-eared cats. Direct sequencing of 63 cats
determined that all 21 Scottish shorthair cats were homozygous for
the wild-type allele, two Scottish fold cats were homozygous for
the variant allele and 39 Scottish fold cats were heterozygous. A
single Scottish fold cat tested homozygous wild-type.Population screening
Screening of 648 cats representing several breeds and domestic
shorthair cats of unknown ear type demonstrated the c.1024G>T
substitution was detected only in the Scottish fold breed and was
absent in all other populations (Table S3).
Protein domain analysis
The variant leads to a non-conserved p.V342F amino acid sub-
stitution and was predicted highly damaging by PolyPhen-2 (score
0.98). Using PSI-BLAST search the human TRPV4 ankyrin repeat
domain (PDB code: 4dx1) and the brown rat TRPV1 ion channel
protein (PDB code: 3j5p), which both include the cat variant site,
were the top matches. Only three residues are different from
Fig. 3. GWAS identiﬁed region associated with osteochondrodysplasia in Scottish fold cats. a. A Manhattan plot showing the negative log of the probability of association (P-value)
between individual markers and osteochondrodysplasia. Markers are shown in alternating colours representing different chromosomes. The upper plot shows Praw values and the
lower plot shows values after correction for multiple testing (Pgenome). Signiﬁcance of P  1$108 is indicated with a dashed line, a dotted line represents associationwith P  1$104.
b. Haplotype unique to cases in the region of association, spanning from position 24,380,099bp to position 25,202,262bp of cat chromosome D3. The asterisk marks the variant
signiﬁcantly associated with osteochondrodysplasia. The haplotype region contains 24 genes (represented by grey lines), including TRPV4 (indicated in red).
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trates the 3D structure of the cat TRPV4 protein region using human
TRPV4 as a template.
Functional analysis of TRPV4 wild-type and TRPV4 p.V342F in
HEK293 cells
To determine the functional consequences stably transfected
HEK293 Flp-In cells expressing either wild-type or mutant TRPV4
were produced. No TRPV4 was detected in untransfected HEK293
cells24; however, whole cell lysates from transfected cells contained
similar amounts of either wild-type or V342F mutant TRPV4
[Fig. 4(A)e(B)]. In HEK293 cells, TRPV4 has three wild-type iso-
forms; unglycosylated, a form substituted with a high mannose N-
linked oligosaccharide, and a complex N-glycosylated form
[Fig. 4(A)]. When compared to wild-type TRPV4, cells expressing
V342Fmutant TRPV4 containedmore of the highmannose form and
less of the complex glycosylated form. The localization of TRPV4was
examined using cell surface biotinylation and streptavidin pull-
down, followed by immunoblotting to identify and quantitate cell
surface proteins. Compared to the wild-type TRPV4, mutant V342FTRPV4 was poorly expressed at the cell surface [Fig. 4(C)e(D)],
indicating that the variant altered TRPV4 protein trafﬁcking.
Intracellular calcium imaging was used to evaluate channel ac-
tivity. A small increase in the constitutive intracellular calcium
concentration ([Ca2þ]i) was detected in cells expressing wild-type
TRPV4 compared to non-transfected cells. Interestingly, [Ca2þ]i
was much higher in cells expressing TRPV4 V342F [Fig. 5(A)],
indicating that the basal activity of the mutant channels is
increased. The response of the channels to the synthetic TRPV4
agonist GSK1016790A showed that intracellular calcium in non-
transfected cells was not changed by GSK1016790A [Fig. 5(B)]. By
contrast, cells expressing wild-type TRPV4 responded with a dose-
dependent increase in [Ca2þ]i. Cells expressing V342F mutant
TRPV4 also showed a GSK1016790A dose-dependent increase in
[Ca2þ]i, although the response was reduced compared to wild-type
expressing cells and the maximum [Ca2þ]i was signiﬁcantly lower
than in wild-type expressing cells [Fig. 5(B)].
As TRPV4 channels respond to changes in tonicity25, the
response of the wild-type and mutant channels to reduced osmo-
larity was studied [Fig. 5(C)]. Cells expressing wild-type TRPV4
responded to hypotonic conditions with a rapid increase in [Ca2þ]i,
Table I
Sequence variants identiﬁed in the cat TRPV4 gene
Position (genomic DNA)* Sequence change (cDNA)y Location Protein Scottish fold 1 Scottish fold 2 Scottish shorthair DSH 1z DSH 2
g.25129900 c.25 T>C Exon 2 Y9H T/C T/C T/C C/C T/T
g.25129903 c.28G>A Exon 2 A10T G/A G/A G/A G/G G/G
g.25129908 c.33A>G Exon 2 Silent G/G A/G A/G A/A A/A
g.25129911 c.63T>C Exon 2 Silent C/C T/C T/C T/T T/T
g.25129944 c.69C>T Exon 2 Silent C/C C/C C/T 0 C/C
g.25130127 c.252C>T Exon 2 Silent C/T C/C C/C C/C C/C
g.25132506 c. 387-69C>T Intron 2 C/T C/T C/T C/C C/C
g.25132759 c.559þ12A>G Intron 3 G/A G/A G/A G/G A/A
g.25136691 c.712þ31A>G Intron 4 A/G G/G G/G A/A A/A
g.25136847 c.712þ166C>G Intron 4 G/C G/C C/C G/G 0
g.25136866 c.712þ185C>T Intron 4 T/C T/C C/C T/T 0
g.25137266 c.713-152G>A Intron 4 A/G A/G A/G A/A A/A
g.25137280 c.713-138C>T Intron 4 C/T C/T C/T C/C C/C
g.25138284 c.854-87T>C Intron 5 C/T C/T C/T C/C 0
g.25138288 c.854-83T>C Intron 5 C/T C/T C/T C/C 0
g.25138480 c.963A>C Exon 6 Silent A/C A/C A/C C/C A/A
g.25138541 c.1024G>T Exon 6 V342F G/T G/T G/G G/G G/G
g.25138621 c.1104T>C Exon 6 Silent T/C T/C T/C T/T T/T
g.25140888 c.1153-20C>T Intron 6 C/T C/C C/C C/C C/C
g.25140902 c. 1153-6G>T Intron 6 G/T G/G G/G G/G G/G
g.25142301 c. 1333-17T>C Intron 7 C/T C/T C/C T/T T/T
g.25143778 c.1659-66T>C Intron 10 T/T T/C T/T C/C 0
g.25143830 c. 1659-14C>T Intron 10 C/C C/C C/T C/C C/C
g.25144020 c.1824þ10C>T Intron 11 T/C C/C C/C T/T T/T
g.25146975 c.2041G>A Exon 13 G681S G/G G/A G/G G/G G/G
g.25149751 c.2387G>A Exon 15 S796N G/A G/A G/A G/G G/G
* Numbering refers to chromosome D3 accession ID GCA_000181335.2.
y Numbering refers to accession number XM_003994850.1.
z Domestic shorthair. Variations that change the amino acid sequence are highlighted in grey. The heterozygous change leading to a p.V342F amino acid substitution in
Scottish fold cats is bolded.
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V342F expressing cells to hypotonic conditions was similar; how-
ever, the peak response is greater and the increase in [Ca2þ]i during
the sustained phase is higher, even when the higher resting [Ca2þ]i
is taken into account [Fig. 5(D)].
Another physiological TRPV4 activation mechanism, PAR2
stimulation of TRPV4 signalling, was investigated. Experimentally,
PAR2 can be activated by synthetic peptides that mimic the teth-
ered ligand and the response of HEK293 cells expressing wild-type
and V342F mutant TRPV4 to the PAR2 activating peptide SLIGRL
was tested. As previously reported, untransfected HEK293 cells
showed a rapid increase in [Ca2þ]i reﬂecting release from intra-
cellular stores26. In cells expressing wild-type TRPV4 this was fol-
lowed by a sustained increase in [Ca2þ]i when compared to the
transient response seen in untransfected HEK293 cells [Fig. 5(E)].
TRPV4 V342F-expressing cells also had a sustained increase in
[Ca2þ]i in response to PAR2 activation, and [Ca2þ]i remained higher
than in wild-type expressing cells throughout. However, the
baseline adjusted increase in [Ca2þ]i was similar in wild-type and
mutant expressing cells indicating that the magnitude of the
response was similar [Fig. 5(F)].
Discussion
TRPV4 is expressed in a range of tissues, including chondrocytes,
osteoblasts and osteoclasts, where its correct activity is crucial for
cell differentiation and tissue homeostasis5,27,28. Accordingly, TRPV4
mutations are responsible for a spectrum of dominantly inherited
human skeletal dysplasias, including, autosomal dominant bra-
chyolmia (OMIM 113500), spondylometaphyseal dysplasia
Kozlowski type (OMIM 1842522), and metatropic dysplasia (OMIM
156530)29e31, as well as a premature arthropathy affecting hands
and feet, familial digital arthropathy brachydactyly (OMIM
606835)24. The TRPV4 skeletal dysplasias show remarkablephenotypic variability and are sometimes accompanied by neuro-
degenerative disorders2,24,32e36. The skeletal dysplasia TRPV4 mu-
tations that have been examined functionally cause a gain of
function and there is evidence that the resulting change in channel
conductancedetermines the severityof the phenotype37.While gain
of function mutations are responsible for obvious human skeletal
malformations, the complete loss of functional TRPV4 has surpris-
ingly little effect on skeletal development in mice5,28.
The TRPV4 protein has six transmembrane domains and large N-
andC-terminal cytoplasmicdomains. TheN-terminal regioncontains
a single proline-rich domain and six ﬁnger-loop forming ankyrin
repeat domains38,39. The N- and C-terminal cytoplasmic domains
play an important role in forming the functional tetrameric cation
channel, in addition to anchoring the protein to the cytoskeleton and
permitting interactions with other proteins39e42. The dominantly
inherited foldedearandosteochondrodysplasia inScottish fold cats is
associated with a p.V342F substitution (c.1024G>T) in the ﬁfth
ankyrin repeat within the N-terminal cytoplasmic domain (Fig. S5).
While the same amino acid substitution has been reported in a hu-
man patient with metatropic dysplasia, the mutation has not been
functionally characterized43. Puriﬁed recombinant ankyrin repeat
domains containing the V342F mutation have reduced thermal sta-
bility compared to wild-type domains and signiﬁcantly weakened
ATP binding even though V342 has no direct interactionwith ATP38.
In wild-type TRPV4, ATP binding leads to a more compact structure
made possible by ﬂexibility in ﬁnger loop 3 in the ankyrin repeat
region which stabilizes the N-terminal domain38. ATP sensitises
TRPV4 channel activity and so the combination of reduced thermal
stability, and altered ATP binding can begin to explain why the
p.V342F mutation is pathogenic44.
To overcome the calcium toxicity that results from extended
TRPV4 overexpression, a system was used where TRPV4 is only
expressed after induction with tetracycline. This system allows
TRPV4 trafﬁcking to the cell surface to be readily compared. TRPV4
Fig. 4. Wild-type and p.V342F mutant TRPV4 expression in stably transfected HEK293 cells. (A) Immunodetection of TRPV4 and b-actin (loading control) in whole cell lysates. Three
TRPV4 isoforms were detected; an unglycosylated form (1), a form substituted with a high mannose N-linked oligosaccharide (2), and a form where the high mannose oligo-
saccharide had been modiﬁed to a complex glycan (3). (B) Quantitating all three TRPV4 bands showed that wild-type and V342F mutant TRPV4 were expressed at similar levels
(P ¼ 0.57). (C) Cell surface proteins were biotinylated then isolated using streptavidin beads and TRPV4, b-actin and transferrin receptor (loading control) detected by immuno-
blotting. The absence of a b-actin signal conﬁrms minimal contamination with intracellular proteins. (D) Quantitation of the TRPV4/transferrin receptor ratio shows that V342F
mutant TRPV4 is poorly expressed at the cell surface compared to wild-type TRPV4 (P ¼ 0.0006). Each point in (B) and (D) is a determination from an individual well. De-
terminations of multiple wells in two independent experiments are shown. Graphs show mean ± S.E.M. Data sets were compared with the Student's t test.
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surface45. Two lines of evidence indicate that the V342F mutation
impairs channel assembly and trafﬁcking. In whole cell lysates,
mutant TRPV4 has less complex N-linked glycosylation and
increased high mannose glycosylation, indicating delayed transit
from the ER to the Golgi. Secondly, reduced cell surface expression
of the mutant channels conﬁrms that intracellular trafﬁcking is
disturbed. Thus, the V342F variant likely changes the structure and
stability of the N-terminal region, protein interactions critical for
tetramer formation and/or stability are compromised and tetramer
formation is delayed.
Even though fewer mutant channels were present at the cell
surface, in unstimulated conditions the intracellular calcium con-
centration was higher in cells expressing mutant TRPV4 channels
than in wild-type expressing cells. This is consistent with electro-
physiology studies that show TRPV4 skeletal dysplasia mutations
increase the channel basal open probabilities37. Wild-type and
mutant channels responded differently to a range of activating
stimuli. The dose response of wild-type andmutant channels to the
synthetic agonist GSK1016790A was similar, indicating that the
drug was able to efﬁciently activate both channels. Despite this, the
maximum response to GSK1016790A was lower in mutant
expressing cells. Since GSK1016790A is thought to drive TRPV4 to
its maximum activity37, the reduced maximum response likely re-
ﬂects reduced cell surface expression of V342F mutant channels.
The V342F mutation did not impact the response of the channels toPAR2 stimulation; however, a gain of function was seen in the
response of the mutant channels to hypotonic conditions. V342F
expressing cells showed a greater maximum response and had
higher sustained intracellular calcium than wild-type expressing
cells even after adjusting for the higher basal activity, indicating the
mutant channels are more sensitive to hypotonicity thanwild-type
channels. By contrast, other TRPV4 skeletal dysplasia mutants,
D333G, R594H and A716S, showed either reduced or no activation
by hypotonic conditions in transiently transfected HEK293 cells46.
This could reﬂect different experimental conditions but likely in-
dicates that the downstream pathogenic consequences of TRPV4
mutations are complex and their inﬂuence on any individual
channel property is only partly informative. Together, these data
demonstrate that TRPV4 wild-type and V342F channels behave
very differently in response to a synthetic agonist and physiological
activation mechanisms, supporting the conclusion that the TRPV4
V342F substitution is pathogenic and causes the bone and joint
phenotype in Scottish fold cats.
Interestingly, the skeletal elements that are affected by the
TRPV4 V432F mutation are different in humans and cats. The child
with the V342F mutation was diagnosed with metatropic
dysplasia43. While only limited clinical information was reported,
the patient had a short trunk and kyphoscoliosis. A review of eleven
metatropic dysplasia patients from 20weeks gestation to 70 years of
age found that progressive and severe kyphoscoliosis was a promi-
nent feature47. Other common features included platyspondyly,
Fig. 5. Intracellular calcium levels in stably transfected HEK293 cells. (A) Constitutive internal ﬂuorescence ratio (**P < 0.01, ****P < 0.0001, one way ANOVA). (B) Changes in
intracellular calcium concentration in response to the synthetic TRPV4 agonist GSK1016790A. Cells expressing wild-type TRPV4 showed a dose dependent increase in intracellular
calcium that reached a plateau at higher concentrations. Cells expressing V342F mutant TRPV4 had higher intracellular calcium at low drug doses and reduced responses to
GSK1016790A at 107.0.and 106.5 M (*P < 0.05, two way ANOVA). (C) Changes in intracellular calcium concentration in response to hypotonicity (240mOsm). The response is
characterised by a rapid rise in intracellular calcium followed by a period of lower but sustained increase in intracellular calcium over basal levels. (D) To compare the magnitude of
the hypotonicity responses the constitutive ﬂuorescence ratio at time 0 (unstimulated) was subtracted from all other time points. Cells expressing V342F mutant TRPV4 had a higher
peak response and maintained a higher response thanwild-type expressing cells over the course of the experiment (*P < 0.05, two way ANOVA). (E) Changes in intracellular calcium
in response to PAR2 activating peptide (PAR2-AP). There is a rapid increase in intracellular calcium reﬂecting release from internal stores followed by a period of sustained elevated
intracellular calcium in cells expressing wild-type and mutant TRPV4. (F) To compare the magnitude of the PAR2 responses the unstimulated ﬂuorescence ratio at time 0 was
subtracted from all other time points. When compared in this way wild-type and V342F mutant TRPV4 responded in a similar manner to PAR2 activation although the peak
response was higher in mutant expressing cells than wild-type expressing cells (*P < 0.05, two way ANOVA). All graphs show mean ± S.E.M.
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feet had generalised brachydactyly but no major deformities or
abnormal bone growth. By contrast, the distal fore and hindlimbs
are severely affected in Scottish fold cats, while the long bones and
the spine are relatively spared. The effects of TRPV4 variants on
different skeletal elements could reﬂect regional species speciﬁc
differences in biomechanical properties. The biomechanical forces
on the spine in a bipedal human are different to those in a quad-
ruped cat48, and similarly, forces through the feet in a cat that bothjumps up and lands from heights will be greater than in most
humans. TRPV4 is a mechanosensor in chondrocytes49. Our data
shows V342F mutant TRPV4 has an elevated response to hypoto-
nicity, a surrogate measure of mechanical stress, compared to wild-
type TRPV4 and this altered transduction of mechanical signals
likely inﬂuences chondrocyte intracellular responses and ultimately,
the disease presentation.
Dissecting the complex downstream consequences of TRPV4
skeletal dysplasia variants will require the appropriate cell types e
B. Gandolﬁ et al. / Osteoarthritis and Cartilage 24 (2016) 1441e1450 1449chondrocytes, osteoblasts, and osteoclasts e expressing wild-type
and mutant TRPV4 alleles, rather than widely used heterologous
cell expression systems. Chondrocytes from patients with TRPV4
variants are generally inaccessible and until now the only animal
models that have been produced are transgenic mice expressing
the Trpv4 V620I or R594H skeletal dysplasia mutations50,51 under
the control of the Col2a1 promoter. While these mice had a range of
skeletal abnormalities similar to those found in humanpatients, the
TRPV4 R594H transgenic mice were generally more severely
affected than expected from the intermediate human spondylo-
metaphyseal dysplasia Kozlowski type that results from the R594H
mutation50. This failure to accurately reproduce the human
phenotype could stem from both inappropriately high TRPV4
expression in cartilage and inappropriate expression in the hyper-
trophic region of the growth plate cartilage. While the Col2a1
promoter is active in the hypertrophic region and the TRPV4
transgene product was expressed there50,51, TRPV4 is not normally
expressed in these terminally differentiated chondrocytes24. Access
to a naturally-occurring TRPV4 variant in a large animal model
opens the door to further functional studies concerning how and
why the mutation affects cartilage and bone development, and the
pathogenesis of accelerated osteoarthritis.
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